Announced details
Drug discovery research, medicinal chemistry, and discovery of novel chemical scaffolds for PI3K/mTOR inhibitors
Inhibitory activity against PI3Kα was demonstrated (figures not disclosed).
The research results were generated in collaboration with the research team. Capital and personnel relationships are not disclosed.
株式会社理論創薬研究所 is the research institution and company that developed DeepSARM, an AI-based drug discovery platform. Axcelead Drug Discovery Partners株式会社 is identified as a research team. Other information, including location, representative, business activities, capital and year of establishment, is not disclosed.
Fujisawa, Kanagawa Prefecture (the company's head office)
By extending the technology to drug discovery targets in new pipelines, it is expected to contribute to the creation of novel compounds and greater efficiency in drug discovery research.
The company does not address Contract Value / Offering price.
ChemMedChem, Wiley, and Chemistry Europe
| Item | Details |
|---|---|
| Names of Products / Services Covered | DeepSARM, Boltz-2, PI3K/mTOR inhibitors |
| Counterparty | 株式会社理論創薬研究所, Axcelead Drug Discovery Partners株式会社 |
| Counterparty overview | 株式会社理論創薬研究所 is the research institution and company that developed DeepSARM, an AI-based drug discovery platform. Axcelead Drug Discovery Partners株式会社 is identified as a research team. Other information, including location, representative, business activities, capital and year of establishment, is not disclosed. |
| Relationship with the Company | The research results were generated in collaboration with the research team. Capital and personnel relationships are not disclosed. |
| Applicable area | Drug discovery research, medicinal chemistry, and discovery of novel chemical scaffolds for PI3K/mTOR inhibitors |
| Location | Fujisawa, Kanagawa Prefecture (the company's head office) |
| Quantitative Effects | Inhibitory activity against PI3Kα was demonstrated (figures not disclosed). |
| Impact on Business Performance | By extending the technology to drug discovery targets in new pipelines, it is expected to contribute to the creation of novel compounds and greater efficiency in drug discovery research. |
| Source | ChemMedChem, Wiley, and Chemistry Europe |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To validate the effectiveness of the novel chemical scaffold discovery technology and demonstrate its potential to efficiently generate new chemical structures that are difficult to identify through conventional drug discovery research.